New Jersey's Advisory Panel on Federal Health Care Reform has issues a report which says any health care reform plans that include price controls could seriously harm the state's economy because of the large number of people working in the drug and health products industry. The report urges the state's congressional delegation to oppose any plan that includes price controls or that would impose a complicated regulatory system on health care prices.
While emphasizing the importance of achieving universal coverage, the report does not take a stand on employer mandates and does not recommend any source of funding for universal coverage. But it does recommend a wide degree of latitude for states to pursue their own health reform initiatives, and notes that in most federal programs, NJ gives more than it gets back.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze